Welcome to our website!
Deutsche Español français italiano português 日本語 한국어 العربية русский bahasa Indonesia Tiếng Việt

Product Catalog

Rapid Product Index

Recommended Products

Friend Links

Your Location：Home>Product Center >> Pharmaceutical API >> Entecavir
  • Entecavir
Name:Entecavir
CAS No:142217-69-4

PRODUCT DESCRIPTION

  Entecavir  Intermediates click here

【Name】

Entecavir
【CAS Registry number】
142217-69-4
【Synonyms】
2-amino-9-[(3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-methylidene-cyclopentyl]-3H-purin-6-one
ETV
6H-Purin-6-one, 2-amino-1,9-dihydro-9-((1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl)-
2-amino-9-[(1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-methylidene-cyclopentyl]-3H-purin-6-one
SQ 34676
BMS 200475
Baraclude
6H-Purin-6-one,2-amino-1,9-dihydro-9- [(1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2- methylenecyclopentyl]-
Taizhou hikong chemical sell Entecavir
Entecavi
Enteca
Entecavir(monohydrate)--Crude Product
【Molecular Formula】
C12H15N5O3 (Products with the same molecular formula)
【Molecular Weight】
277.28
【Inchi】
InChI=1/C12H15N5O3/c1-5-6(3-18)8(19)2-7(5)17-4-14-9-10(17)15-12(13)16-11(9)20/h4,6-8,18-19H,1-3H2,(H3,13,15,16,20)/t6-,7+,8-/m0/s1
【Canonical SMILES】
C=C1C(CC(C1CO)O)N2C=NC3=C2NC(=NC3=O)N
【Isomers smiles】
C=C1[C@@H]([C@H](CC1N2C=NC3=C2NC(=NC3=O)N)O)CO
【MOL File】
142217-69-4.mol

Chemical and Physical Properties

【Appearance】
white to off-white/yellow crystalline powder
【Density】
1.81g/cm3
【Melting Point】
249-252°C
【Boiling Point】
734.2 °C at 760 mmHg
【Refractive Index】
1.837
【Flash Point】
397.9 °C
【Solubilities】
In water, 2.4X10+3 mg/L, temp not specified
【Color/Form】
White to off white powder
【Computed Properties】
Molecular Weight:277.2792 [g/mol]
Molecular Formula:C12H15N5O3
XLogP3:-0.8
H-Bond Donor:4
H-Bond Acceptor:3
Rotatable Bond Count:2
Tautomer Count:9
Exact Mass:277.117489
MonoIsotopic Mass:277.117489
Topological Polar Surface Area:126
Heavy Atom Count:20
Formal Charge:0
Complexity:480
Isotope Atom Count:0
Defined Atom Stereocenter Count:2
Undefined Atom Stereocenter Count:1
Defined Bond Stereocenter Count:0
Undefined Bond Stereocenter Count:0
Covalently-Bonded Unit Count:1
Feature 3D Acceptor Count:3
Feature 3D Donor Count:5
Feature 3D Cation Count:1
Feature 3D Ring Count:3
Effective Rotor Count:2.8
Conformer Sampling RMSD:0.6
CID Conformer Count:21

Safety and Handling

【Formulations/Preparations】
0.05 mg/mL (Rx) Baraclude (citric acid, maltitol, methylparaben, orange flavor, sodium citrate) /Oral solution/
0.5 mg /tablet/ (Rx) Baraclude (crospovidone, hypromellose, lactose monohydrate, magnesium stearate, microcrystalline cellulose, polyethylene glycol 400, polysorbate 80, povidone, titanium dioxide).
1 mg /tablet/ (Rx) Baraclude (crospovidone, hypromellose, iron oxide red, lactose monohydrate, magnesium stearate, microcrystalline cellulose, polyethylene glycol 400, povidone, titanium dioxide).
【Exposure Standards and Regulations】
The Approved Drug Products with Therapeutic Equivalence Evaluations List identifies currently marketed prescription drug products, incl entecavir, approved on the basis of safety and effectiveness by FDA under sections 505 of the Federal Food, Drug, and Cosmetic Act.
【Octanol/Water Partition Coefficient】
log Kow = -0.49 (est)
【Disposal Methods】
SRP: The most favorable course of action is to use an alternative chemical product with less inherent propensity for occupational exposure or environmental contamination. Recycle any unused portion of the material for its approved use or return it to the manufacturer or supplier. Ultimate disposal of the chemical must consider: the material's impact on air quality; potential migration in soil or water; effects on animal, aquatic, and plant life; and conformance with environmental and public health regulations.

Use and Manufacturing

【Usage】

 Entecavir (CAS NO.142217-69-4) is used to treat chronic hepatitis B. And it also helps prevent the hepatitis B virus from multiplying and infecting new liver cells. Besides, Entecavir is also indicated for the treatment of chronic hepatitis B in adults with HIV/AIDS infection, but Entecavir is not active against HIV.

Biomedical Effects and Toxicity

【Therapeutic Uses】
Entecavir is indicated for the treatment of chronic hepatitis B virus infection in adults with evidence of active viral replication and either evidence of persistent elevations in serum aminotransferases (ALT or AST) or histologically active disease. This indication is based on histologic, virologic, biochemical and serologic responses after one year of treatment in nucleoside-treatment-naive and lamivudine- resistant adult patients with HBeAg-positive or HBeAg-negative chronic HBV infection with compensated liver disease and on more limited data in adult patients with HIV/HBV co-infection who have received prior lamivudine therapy. /Included in US product labeling/
【Biomedical Effects and Toxicity】
The bioavailability of /entecavir/ tablets was /equivalent/ to the oral solution.
Oral administration of 0.5 mg of entecavir given with a standard high fat meal resulted in a delayed in absorption (1 to 1.5 hours fed vs. 0.75 hours fasted), a decrease in Cmax of 44% to 46%, and a decrease in AUC of 18% to 20%.
/The estimated apparent volume of distribution is in excess of total body water/, entecavir is extensively distributed into tissues.
/Binding of entecavir to human serum proteins in vitro is/ low (13%)
Time to peak plasma concentration /for entecavir was/ 0.5 to 1.5 hours following oral administration. Peak plasma concentration /levels for entecavir were/ 4.2 ng/mL and 8.2 ng/mL /for the 0.5 mg and 1 mg doses, respectively./ The area under the plasma concentration-time curve (AUC) at steady state was achieved after 6 to 10 days of once daily administration with approximately 2-fold accumulation.
/Entecavir is predominately eliminated by the kidney with urinary recovery of unchanged drug ranging from/ 62% to 73% of the administered dose. Renal clearance is independent of dose and ranges from 360 to 471 mL/min suggesting both glomerular filtration and net tubular secretion.
Entecavir is distributed into the milk of rats. It is not known whether entecavir is distributed into human milk.

Environmental Fate and Exposure Potential

【Environmental Fate/Exposure Summary】
TERRESTRIAL FATE: Based on a classification scheme(1), an estimated Koc value of 60(SRC), determined from a water solubility of 2.4X10+3 mg/L(2) and a regression-derived equation(3), indicates that entecavir is expected to have high mobility in soil(SRC). Volatilization of entecavir from moist soil surfaces is not expected to be an important fate process(SRC) given an estimated Henry's Law constant of 1.8X10-21 atm-cu m/mole(SRC), using a fragment constant estimation method(4). Entecavir is not expected to volatilize from dry soil surfaces(SRC) based upon an estimated vapor pressure of 4.8X10-18 mm Hg(SRC), determined from a fragment constant method(5). Biodegradation data were not available(SRC, 2005).
AQUATIC FATE: Based on a classification scheme(1), an estimated Koc value of 60(SRC), determined from a water solubility of 2.4X10+3 mg/L(2) and a regression-derived equation(3), indicates that entecavir is not expected to adsorb to suspended solids and sediment(SRC). Volatilization from water surfaces is not expected(3) based upon an estimated Henry's Law constant of 1.8X10-21 atm-cu m/mole(SRC), developed using a fragment constant estimation method(4). According to a classification scheme(5), an estimated BCF of 7.7(SRC)from its water solubility and a regression-derived equation(3), suggests the potential for bioconcentration in aquatic organisms is low(SRC). Biodegradation data were not available(SRC, 2005).
ATMOSPHERIC FATE: According to a model of gas/particle partitioning of semivolatile organic compounds in the atmosphere(1), entecavir, which has an estimated vapor pressure of 4.8X10-18 mm Hg at 25 deg C(SRC), determined from a fragment constant method(2), is expected to exist solely in the particulate phase in the ambient atmosphere. Particulate-phase entecavir may be removed from the air by wet and dry deposition(SRC). Entecavir does not contain chromophores that absorb at wavelengths >290 nm and therefore is not expected to be susceptible to direct photolysis by sunlight(SRC).

RELATED PRODUCTS

Customer Service Hotline
Tel:+86 519 82111935
Email:info@feifanchem.com
Mobile:+86 15195055733(whats)
Address:No.4 HouYang chemical industrial park.Changzhou,Jiangsu,province,P.R.China.
CopyRight 2022 Extraordinary Pharmatech www.feifanchem.com     

  Send Email

Skype  Skype

3391543003  3391543003

 +86 15195055733

LiveChatclose